4D Molecular Therapeutics, Inc. Common Stock(FDMT)

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

FDMT $11.80
Snapshot
$11.80
52-Week Range
$4.14 – $14.00
YTD
+61.16%
IV Rank (30D)
15.62
Straddle Price
$3.38
P/C Vol Ratio
0.54
Market Cap
$0.6B
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.57%
Beta vs SPY1.00
Cost of Equity (CAPM)10.07% (VRP-adj)
WACC10.08%
Volatility Risk Premium+76.4pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+30.0%
DCF Horizon10 years explicit + fade
Forward Tilt (NTM/TTM)×1.10 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.1B
Return on Equity (TTM)-35.6%
Book / Price68.5% — banking bias active (P/B is primary)
Gross Margin (TTM)100.0%
FCF Margin (TTM)-146.8%
Debt / Equity0.00
Quality Score3/6 — normal (10y DCF)
SMA 50$10.36 (Market Anchor value)
SMA 20 / Bollinger Mid$12.01
Bollinger Width / SMA20235.4% (drives anchor stability)
Net Debt$-0.1B
Market Cap$1B
Peers used for multiples: AMGN, APGE, BIIB, EXEL, GILD, KRYS, MRNA, NBIX, RVMD, TECH (SIC-code peers; ETF co-membership was sector-incoherent)
Model Conviction
88%
20-Day Fair Value
≈ by Aug 19, 2026
ACTIVE
$12.43
α +6.0% rank 94%
40-Day Fair Value
≈ by Sep 17, 2026
ACTIVE
$13.49
α +15.0% rank 97%
60-Day Fair Value
≈ by Oct 16, 2026
ACTIVE
$13.50
α +15.0% rank 96%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 25.3× · 7 peers
Peer EV/EBITDA n/a 0% median 15.7× · 7 peers
Peer P/B $54.48 19% median 7.2× · 10 peers
Peer P/S $9.40 19% median 5.8× · 8 peers
Market Anchor (SMA50) $10.36 63% stability 66% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-07-21 · updated
Info
Industry (SIC)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836)
Exchange
XNAS
Market Cap
$0.6B

4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aero…

Summary
composite
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
MonthAvg ReturnYears of Data
Jan -0.70% 6
Feb -8.66% 6
Mar +1.52% 6
Apr -7.31% 6
May -5.97% 6
Jun -1.05% 6
Jul +4.52% 6
Aug -6.69% 5
Sep -4.66% 5
Oct +4.69% 5
Nov +31.32% 5
Dec -1.66% 5
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators
SMA 20: $12.07
SMA 50: $10.40
SMA 200: $9.72
Current: $11.73
EMA 12: $11.62
EMA 26: $11.35
MACD: 0.2700 | Signal: -0.2307
BULLISH
ADX (14): 23.27
WEAK TREND
+DI: 22.76
−DI: 20.10
Momentum Oscillators
RSI (14): 53.89
NEUTRAL
Stoch %K: 28.29
Stoch %D: 19.56
Williams %R: -55.56
Volume & Volatility
BB Upper: $13.62
BB Lower: $10.53
NEUTRAL
OBV: 19,171,443
Vol SMA 20: 1,026,483
Vol ROC: 2.07%
ATR: $0.88
True Range: $0.96
HV 20: 76.9%
HV 30: 77.4%
HV 60: 79.6%

Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-07-22T00:00:00 – 2026-07-20T00:00:00
AI Analysis

Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.

Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.

News
Earnings History
8 of 9 under expected move
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2024-08-08 After-Close 12.02% 1.14% 0.09x Within
2024-11-13 Pre-Market 7.27% 0.13% 0.02x Within
2025-01-10 After-Close 10.71% 9.50% 0.89x Within
2025-02-28 After-Close 56.84% 8.61% 0.15x Within
2025-05-08 Pre-Market 106.06% 3.65% 0.03x Within
2025-08-11 After-Close 10.85% 11.21% 1.03x Exceeded
2025-11-10 After-Close 12.78% 6.19% 0.48x Within
2026-01-07 After-Close 14.26% 5.18% 0.36x Within
2026-03-20 After-Close 46.77% 6.06% 0.13x Within
Options Activity
IV Rank (30D)
15.62
IV Rank (7D)
15.62
Avg IV
140.0%
Straddle (30D)
$3.38
Straddle (7D)
$3.38
P/C Volume
0.54
Spread Scanner GPU

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
pts EXTREME
ATM — / Wing —
30 DTE / 10d
pts EXTREME
ATM — / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Beta (1Y vs SPY)
1.37
Correlation (SPY)
18.7%
0.03
Ann. Volatility
93.1%
SPY Volatility
12.7%

High volatility - stock moves more than market

Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-06-30
Diluted shares outstanding: 59,512,046 (as of 2026-03-31)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

155 filers53,814,027 shares$492.76M value90.43% of float
# Filer Shares Value % of Total % of Float Period
1 JANUS HENDERSON GROUP PLC 5,247,151 $48.87M 9.92% 8.82% 2026-03-31
2 RA CAPITAL MANAGEMENT, L.P. 5,049,779 $47.01M 9.54% 8.49% 2026-03-31
3 GOLDMAN SACHS GROUP INC Custodian 4,205,438 $39.15M 7.95% 7.07% 2026-03-31
4 BlackRock, Inc. Custodian 4,145,303 $38.59M 7.83% 6.97% 2026-03-31
5 Novo Holdings A/S 3,650,737 $33.99M 6.90% 6.13% 2026-03-31
6 BVF INC/IL 2,879,289 $26.81M 5.44% 4.84% 2026-03-31
7 STATE STREET CORP 2,707,875 $25.21M 5.12% 4.55% 2026-03-31
8 VANGUARD GROUP INC Custodian 3,093,527 $23.20M 4.71% 5.20% 2025-12-31
9 VANGUARD CAPITAL MANAGEMENT LLC 2,195,578 $20.44M 4.15% 3.69% 2026-03-31
10 ARMISTICE CAPITAL, LLC 2,000,000 $18.62M 3.78% 3.36% 2026-03-31
11 ADAGE CAPITAL PARTNERS GP, L.L.C. 1,605,156 $14.94M 3.03% 2.70% 2026-03-31
12 FEDERATED HERMES, INC. 1,432,260 $13.33M 2.71% 2.41% 2026-03-31
13 Trails Edge Capital Partners, LP 1,302,917 $12.13M 2.46% 2.19% 2026-03-31
14 GEODE CAPITAL MANAGEMENT, LLC Custodian 1,065,345 $9.92M 2.01% 1.79% 2026-03-31
15 BANK OF AMERICA CORP /DE/ Custodian 974,173 $9.07M 1.84% 1.64% 2026-03-31
16 Evergreen Quality Fund GP, Ltd. 951,474 $8.86M 1.80% 1.60% 2026-03-31
17 DEUTSCHE BANK AG\ Custodian 708,044 $6.59M 1.34% 1.19% 2026-03-31
18 RENAISSANCE TECHNOLOGIES LLC 578,265 $5.38M 1.09% 0.97% 2026-03-31
19 Nuveen, LLC Custodian 561,805 $5.23M 1.06% 0.94% 2026-03-31
20 VANGUARD PORTFOLIO MANAGEMENT LLC 555,829 $5.17M 1.05% 0.93% 2026-03-31
21 MORGAN STANLEY Custodian 672,695 $5.05M 1.02% 1.13% 2025-12-31
22 Parkman Healthcare Partners LLC 522,577 $4.87M 0.99% 0.88% 2026-03-31
23 DIMENSIONAL FUND ADVISORS LP Custodian 522,823 $4.86M 0.99% 0.88% 2026-03-31
24 RTW INVESTMENTS, LP 475,737 $4.43M 0.90% 0.80% 2026-03-31
25 Propel Bio Management, LLC 380,420 $3.58M 0.73% 0.64% 2026-03-31
5 filers$1.06M notional
# Filer Notional Value % of Total Period
1 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $450.60K 42.53% 2026-03-31
2 CITADEL ADVISORS LLC Custodian $272.78K 25.75% 2026-03-31
3 GROUP ONE TRADING LLC Custodian $175.96K 16.61% 2026-03-31
4 JANE STREET GROUP, LLC Custodian $159.20K 15.03% 2026-03-31
5 SIMPLEX TRADING, LLC Custodian $931 0.09% 2026-03-31
5 filers$1.53M notional
# Filer Notional Value % of Total Period
1 JANE STREET GROUP, LLC Custodian $576.29K 37.56% 2026-03-31
2 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $329.57K 21.48% 2026-03-31
3 SIMPLEX TRADING, LLC Custodian $314.68K 20.51% 2026-03-31
4 CITADEL ADVISORS LLC Custodian $220.65K 14.38% 2026-03-31
5 GROUP ONE TRADING LLC Custodian $93.10K 6.07% 2026-03-31
Insider Activity
Latest: 2026-07-14
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-07-14 David Kirn See Remarks Sell (S) −58,333 $12.64 -$737.4K EDGAR
2026-07-02 Scott Bizily Chief Legal Officer Mixed $10.10 -$51.2K EDGAR
2026-06-25 Scott Bizily Chief Legal Officer Mixed $8.07 -$77.1K EDGAR
2026-06-23 David Kirn See Remarks Sell (S) −114,746 $10.47 -$1.20M EDGAR
2026-06-18 SUSANNAH GRAY Director Grant (A) +50,000 opt EDGAR
2026-06-18 GLENN SBLENDORIO Director Grant (A) +50,000 opt EDGAR
2026-06-18 JOHN F MILLIGAN Director Grant (A) +75,000 opt EDGAR
2026-06-18 Shawn Tomasello Director Grant (A) +50,000 opt EDGAR
2026-06-18 CHARLES THEUER Director Grant (A) +50,000 opt EDGAR
2026-06-18 Jacob Chacko Director Grant (A) +50,000 opt EDGAR
2026-06-18 Nancy Miller-Rich Director Grant (A) +50,000 opt EDGAR
2026-06-02 David Kirn See Remarks Sell (S) −1,922 $10.02 -$19.3K EDGAR
2026-03-27 Scott Bizily Chief Legal Officer Grant (A) +217,000 opt EDGAR
2026-03-27 David Kirn Chief Executive Officer Grant (A) +750,000 opt EDGAR
2026-03-27 Christopher Paul Simms See Remarks Grant (A) +219,000 opt EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
15 insiders · @ $11.73
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Viking Global Opportunities Illiquid Investments Sub-Master LP 10%+ Owner 4,787,914 $56.16M $108.80M 1 2023-05-11
2 RA Capital Healthcare Fund LP 10%+ Owner 4,563,211 $53.53M $0 1 2024-12-10
3 Rose Sharon Shabet 10%+ Owner 4,247,914 $49.83M -$84.37M 1 2024-01-05
4 Viking Global Opportunities Portfolio GP LLC 10%+ Owner 3,937,914 $46.19M $177.10M 1 2020-12-17
5 David Kirn See Remarks 1,499,877 $17.59M -$10.23M 18 2026-07-14
6 DAVID SCHAFFER Director 925,935 $10.86M -$3.01M 4 2021-10-22
7 TONY DUNG LING YAO Director 458,190 $5.37M $9.78M 1 2020-12-17
8 JOHN F MILLIGAN Director 100,000 $1.17M $2.30M 7 2026-06-18
9 BVF I GP LLC 87,911 $1.03M $0 1 2024-11-13
10 Ashoo Gupta VP, Finance and Controller 46,914 $550.3K -$6.7K 2 2026-03-24
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
Notice of Proposed Sale (Form 144)
Latest: 2026-07-10
Last 30d: 5 filings · $2.1M notice value  ·  Last 90d: 6 filings · $2.1M notice value · 2 unique filers · 100% under 10b5-1 plans

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. Amendments (Form 144/A) and post-cancellation refilings can inflate this if you sum naively; the rollup above excludes filings with zero stated value.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Top 90-day filers: David Kirn (4, $2.0M) · SCOTT BIZILY (2, $187K)
Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-07-10 David Kirn Officer 15,725 $193.6K 2026-07-10 Goldman Sachs & Co. LLC 10b5-1 EDGAR
2026-07-09 David Kirn Officer 42,608 $549.2K 2026-07-09 Goldman Sachs & Co. LLC 10b5-1 EDGAR
2026-06-30 SCOTT BIZILY Officer 6,566 $84.6K 2026-06-30 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-06-23 SCOTT BIZILY Officer 9,810 $102.2K 2026-06-23 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-06-22 David Kirn Officer 114,746 $1.20M 2026-06-22 Goldman Sachs & Co. LLC 10b5-1 EDGAR
2026-06-01 David Kirn Officer 1,922 $18.7K 2026-06-01 Goldman Sachs & Co. LLC 10b5-1 EDGAR
2025-12-16 SCOTT BIZILY Officer 1,635 $17.9K 2025-12-16 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2025-11-17 SCOTT BIZILY Officer 1,635 $17.6K 2025-11-17 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2025-10-24 SCOTT BIZILY Officer 1,816 $18.2K 2025-10-24 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2025-09-23 SCOTT BIZILY Officer 7,312 $54.1K 2025-09-23 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed.
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

P/B Ratio1.3
P/S Ratio6.5
EV/EBITDA-2.9
TTM Revenue$0.1B
TTM Net Income$-0.2B
TTM EPS$-2.57
ROE-35.6%